Antibodies that bind to human programmed death ligand 1 (PD-L1)
View Patent ↗The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided.
1. An isolated antibody or antigen binding fragment thereof that specifically binds human programmed death ligand 1 (PD-L1) as set forth in SEQ ID NO: 37 and comprises three light chain CDRs of CDRL1, CDRL2 and CDRL3 and three heavy chain CDRs of CDRH1, CDRH2 and CDRH3, wherein:
(a) CDRL1 is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:9, and SEQ ID NO:21;
(b) CDRL2 is SEQ ID NO:2;
(c) CDRL3 is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:10, and SEQ ID NO:22;
(d) CDRH1 is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:26, and SEQ ID NO:27;
(e) CDRH2 is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:16, and SEQ ID NO:28; and
(f) CDRH3 is selected from the group consisting of SEQ ID NO:7, SEQ ID NO:17, and SEQ ID NO:29.
2. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the three light chain CDRs are SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and the three heavy chain CDRs are SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.
3. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the three light chain CDRs are SEQ ID NO:9; SEQ ID NO:2 and SEQ ID NO:10 and the three heavy chain CDRs are SEQ ID NO:14, SEQ ID NO:16 and SEQ ID NO:17.
4. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the three light chain CDRs are SEQ ID NO:21, SEQ ID NO:2 and SEQ ID NO:22 and the three heavy chain CDRs are SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:29.
5. The isolated antibody or antigen binding fragment thereof of claim 1 , which comprises a light chain variable region and a heavy chain variable region, wherein:
(a) the light chain variable region is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:13, and SEQ ID NO:25; and
(b) the heavy chain variable region is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:20, and SEQ ID NO:32.
6. The isolated antibody or antigen binding fragment thereof of claim 1 , which comprises a light chain variable region and a heavy chain variable region, wherein:
(a) the light chain variable region is SEQ ID NO:13 and the heavy chain variable region is SEQ ID NO:20;
(b) the light chain variable region is SEQ ID NO:25 and the heavy chain variable region is SEQ ID NO:32, wherein X in SEQ ID NO:32 is Q; or
(c) the light chain variable region is SEQ ID NO:25 and the heavy chain variable region is SEQ ID NO:32, wherein X in SEQ ID NO:32 is pE.
7. The isolated antibody or antigen binding fragment thereof of claim 6 which is an IgG1 antibody.
8. An isolated antibody comprising a light chain variable region of SEQ ID NO:25, a heavy chain variable region of SEQ ID NO:32, and a mouse IgG1 constant region.